2018

13/11/2018 Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial

09/11/2018 Imugene Receives $1.85 million R&D Tax Incentive

04/10/2018 European Society for Medical Oncology President joins Imugene Scientific Advisory Board

01/10/2018 Imugene appoints leading cancer researcher to Scientific Advisory Board

21/09/2018 Imugene commences cGMP manufacture of PD-1 cancer vaccine

18/09/2018 Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board

11/09/2018 Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

23/08/2018 Imugene appoints Dr Mark Marino Chief Medical Officer 

27/07/2018 2018 Bioshares Presentation

23/07/2018 PD-1 cancer vaccine development update

07/06/2018 Capital Raising Presentation

07/06/2018 Prospectus

07/06/2018 Imugene to Raise A$20.1 million

07/06/2018 Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio

05/06/2018 Trading Halt

28/03/2018 Leslie Chong Appointed as Managing Director

18/02/2018 Imugene arginine modulator demonstrates activity in melanoma cancer model

11/02/2018 Novel Anti-PD-1 Mimotope Vaccine Ready for Development

09/02/2018 Imugene hosts investigator meeting for gastric cancer clinical trial

07/02/2018 Cancer vaccine shows early promise in gastric cancer clinical trial

29/01/2018 Business Update – December Quarter Appendix 4C

2017

04/12/2017 International Cancer Specialist Joins Imugene’s SAB

23/11/2017 IMUGENE RAISES $8.7 MILLION

23/11/2017 IMU - Prospectus

23/11/2017 IMU Capital Raising Presentation

23/11/2017 Entitlement Offer - notice to option holders

23/11/2017 Entitlement Offer - notice to ineligible shareholders

23/11/2017 Entitlement Offer – notice to eligible shareholders

24/10/2017 Imugene Limited to Present at Australia Biotech Invest 2017

16/10/2017 Expert briefing and Q&A

11/10/2017 Imugene Receives $1.1 million in Research and Development Tax Refund

06/10/2017 Imugene Investor Presentation

31/08/2017 Imugene commences first patient dosing of HER-Vaxx

21/07/2017 Canadian patent granted for HER-Vaxx

17/07/2017 Investor Presentation July 2017

26/06/2017 Change of Address

30/03/2017 $1.35 million Options Underwritten

27/02/2017 Intellectual Property Strengthened Around Lead Clinical Drug HER-Vaxx

13/02/2017 Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research

09/01/2017 Presentation by Leslie Chong at 9th Annual Biotech Showcase, San Francisco 9 Jan 17